Calcium channel blockers

A pharmaceutical composition for use in treating conditions characterized by aberrant N-type calcium channel activity which composition comprises, in admixture with a pharmaceutically acceptable excipient, a dosage amount effective to modulate N-type calcium channel activity of a compound of the formula

• wherein m is 0, 1 or 2;
• wherein when m is 0, Z is O, when m is 1, Z is N, and when m is 2, Z is C;
• Y is H, OH, NH2, or an organic moiety of 1-20C, optionally additionally containing 1-8 heteroatoms selected from the group consisting of N, P, O, S and halo;
• each 11 and 12 is independently 0-5;
• 13 is 0 or 1;
• each of R1, R2 and R3 is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or each of R1 and R2 may independently be halo, COOR, CONR2, CF3, CN or NO2, wherein R is H or lower alkyl (1-4C) or alkyl (1-6C);
• n is 0 or 1;
• X is a linker;
• with the proviso that Y is not a tropolone, a coumarin, or an antioxidant containing an aromatic group and with the fuirther proviso that if 13 is 0, neither R1 nor R2 can be F in the para position.

A library comprising at least ten different compounds of the formula

• wherein m is 0, 1 or 2;
• wherein when m is 0, Z is O, when m is 1, Z is N, and when m is 2, Z is C;
• Y is H, OH, NH2, or an organic moiety of 1-20C, optionally additionally containing 1-8 heteroatoms selected from the group consisting of N, P, O, S and halo;
• each 11 and 12 is independently 0-5;
• 13 is 0 or 1;
• each of R1, R2 and R3 is independently alkyl (1-6C), aryl (6-10C) or arylalkyl (7-16C) optionally containing 1-4 heteroatoms selected from the group consisting of halo, N, P, O, and S or each of R1 and R2 may independently be halo, COOR, CONR2, CF3, CN or NO2, wherein R is H or lower alkyl (1-4C) or alkyl (1-6C);
• n is 0 or 1;
• and
• X is a linker.